Second Verse Same as the First
Reata, Abbott Ink Another $400M Up-Front Deal
By Marie Powers
Tuesday, December 13, 2011
A year after landing a $450-million up-front deal with Abbott for its lead antioxidant inflammation modulator (AIM) bardoxolone methyl, Reata Pharmaceuticals Inc. hit the rewind button, gaining another one-time $400 million license payment from the pharma giant to develop the rest of its second-generation AIM portfolio.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.